Table 1.
Patients’ baseline characteristics
| Characteristics | Results | % |
|---|---|---|
| Age, years, Mean ± SD | 58.4 ± 10.5 | |
| Sex | ||
| Male | 125 | 60.1 |
| Female | 83 | 39.9 |
| ECOG PS | ||
| 0–1 | 199 | 95.7 |
| 2–3 | 9 | 4.3 |
| Smoking status | ||
| Never | 154 | 74.0 |
| Current or former | 54 | 26.0 |
| Histology | ||
| Adenocarcinoma | 202 | 97.1 |
| Other carcinomas | 6 | 2.9 |
| EGFR mutation status | ||
| Exon 19 deletion | 100 | 48.1 |
| Exon 21 L858R | 90 | 43.3 |
| Uncommon mutation | 18 | 8.6 |
| Disease stage | ||
| III | 17 | 8.2 |
| IV | 191 | 91.8 |
| Tumour metastases | ||
| Brain | 66 | 31.7 |
| Bone | 106 | 51.0 |
| Pleural | 62 | 29.8 |
| Other | 40 | 19.2 |
| Adjuvant treatment | ||
| Yes | 107 | 60.1 |
| No | 71 | 39.9 |
| LIPI | ||
| 0 | 120 | 58.3 |
| 1 | 66 | 32.0 |
| 2 | 20 | 9.7 |
| LMR, Median (IQR) | 3.18 (2.29–4.46) | |
| NLR, Median (IQR) | 3.04 (2.04–4.95) | |
| PLR, Median (IQR) | 157.18 (119.28-224.37) | |
| SII, Median (IQR) | 675.68 (403.14-1133.79) | |
| PNI, Mean ± SD | 45.89 ± 5.67 | |
| AGR, Mean ± SD | 1.52 ± 0.30 | |
| CEA, µg/L, Median (IQR) | 16.77 (4.75–94.30) | |
| CA-125, U/ml, Median (IQR) | 38.80 (18.50-104.80) | |
| CA19-9, U/ml, Median (IQR) | 8.85 (4.10–38.40) | |
SD: standard deviation; IQR: interquartile range; ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; LIPI: lung immune prognostic index; LMR: lymphocyte-monocyte ratio; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; SII: systemic immune-inflammation index; PNI: prognostic nutritional index; AGR: albumin-globulin ratio; CEA: carcinoembryonic antigen; CA: carbohydrate antigen.